

Anaphylaxis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/A154F40A4147EN.html>

Date: September 2022

Pages: 57

Price: US\$ 2,000.00 (Single User License)

ID: A154F40A4147EN

Abstracts

Anaphylaxis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis - Drugs In Development, 2022, provides an overview of the Anaphylaxis (Immunology) pipeline landscape.

Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 6, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Anaphylaxis (Immunology).

The pipeline guide reviews pipeline therapeutics for Anaphylaxis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Anaphylaxis (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Anaphylaxis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Anaphylaxis (Immunology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Anaphylaxis (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Anaphylaxis (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Anaphylaxis - Overview

Anaphylaxis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anaphylaxis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anaphylaxis - Companies Involved in Therapeutics Development

Allakos Inc

Aquestive Therapeutics Inc

ARS Pharmaceuticals Inc

BioArdis LLC

Bryn Pharma LLC

Crossject SA

Hoth Therapeutics Inc

Klaria Pharma Holding AB

Nasus Pharma Ltd

Orexo AB

Pharmacin BV

PureIMS BV

Anaphylaxis - Drug Profiles

AK-006 - Drug Profile

Product Description

Mechanism Of Action

AQST-109 - Drug Profile

Product Description

Mechanism Of Action

History of Events

epinephrine - Drug Profile

Product Description

Mechanism Of Action

History of Events

epinephrine - Drug Profile

Product Description

Mechanism Of Action

epinephrine - Drug Profile

Product Description

Mechanism Of Action

History of Events

epinephrine - Drug Profile

Product Description

Mechanism Of Action

History of Events

epinephrine - Drug Profile

Product Description

Mechanism Of Action

History of Events

epinephrine - Drug Profile

Product Description

Mechanism Of Action

History of Events

epinephrine - Drug Profile

Product Description

Mechanism Of Action

HLK-0006 - Drug Profile

Product Description

Mechanism Of Action

HT-KIT - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile

Product Description

Mechanism Of Action

MRGPRX2 Antagonist - Drug Profile

Product Description

Mechanism Of Action

OX-640 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Anaphylaxis - Dormant Projects

Anaphylaxis - Product Development Milestones

Featured News & Press Releases

Sep 13, 2022: Bryn Pharma announces completion of its pivotal study comparing UTULY epinephrine intranasal spray vs. 0.3 mg epinephrine autoinjector for the treatment of anaphylaxis

Sep 01, 2022: First patent issued in Europe for Orexo's adrenaline product OX640

Jul 11, 2022: Aquestive Therapeutics reports positive results from final two arms of EPIPHAST Trial Supporting performance and real-world functionality of AQST-109 Epinephrine Oral Film

Jul 05, 2022: Orexo's nasal adrenaline rescue medication OX640 enters clinical development

Jun 15, 2022: Aquestive Therapeutics reports positive initial topline data from part 3 of EPIPHAST trial evaluating AQST-109 epinephrine oral Film

Apr 12, 2022: Aquestive Therapeutics reports positive topline data from part 2 of EPIPHAST trial evaluating AQST-109 epinephrine oral film

Mar 17, 2022: Aquestive Therapeutics receives FDA Fast Track Designation for AQST-109 for emergency treatment of allergic reactions including anaphylaxis

Feb 28, 2022: ARS Pharmaceuticals to share new data at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting

Feb 28, 2022: Aquestive Therapeutics presented positive topline Phase 1 results for AQST-109 epinephrine oral film at American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting

Feb 25, 2022: Aquestive Therapeutics reports positive topline data from part 1 of EPIPHAST Trial evaluating AQST-109 epinephrine oral film

Feb 24, 2022: Aquestive Therapeutics announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film

Feb 01, 2022: Phase 1 trial shows epinephrine can meet therapeutic thresholds when administered sublingually

Dec 13, 2021: Aquestive Therapeutics receives written response to pre-IND submission for AQST-109 (epinephrine prodrug sublingual film) and begins recruitment for its epinephrine film pharmacokinetic and safety trial (EPIPHAST)

Dec 02, 2021: Orexo develops a nasal adrenaline medication based on the novel amorphOX platform

Nov 08, 2021: Hoth Therapeutics Inks API and drug product contracts with WuXi STA to advance manufacturing of HT-KIT cancer therapeutic

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Anaphylaxis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Anaphylaxis - Pipeline by Allakos Inc, 2022
Anaphylaxis - Pipeline by Aquestive Therapeutics Inc, 2022
Anaphylaxis - Pipeline by ARS Pharmaceuticals Inc, 2022
Anaphylaxis - Pipeline by BioArdis LLC, 2022
Anaphylaxis - Pipeline by Bryn Pharma LLC, 2022
Anaphylaxis - Pipeline by Crossject SA, 2022
Anaphylaxis - Pipeline by Hoth Therapeutics Inc, 2022
Anaphylaxis - Pipeline by Klaria Pharma Holding AB, 2022
Anaphylaxis - Pipeline by Nasus Pharma Ltd, 2022
Anaphylaxis - Pipeline by Orexo AB, 2022
Anaphylaxis - Pipeline by Pharmacin BV, 2022
Anaphylaxis - Pipeline by PureIMS BV, 2022
Anaphylaxis - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Anaphylaxis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Anaphylaxis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/A154F40A4147EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A154F40A4147EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

